STOCK TITAN

BioAge Labs, Inc. - BIOA STOCK NEWS

Welcome to our dedicated page for BioAge Labs news (Ticker: BIOA), a resource for investors and traders seeking the latest updates and insights on BioAge Labs stock.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) is a Swedish research-based biopharmaceutical company that focuses on developing innovative treatments to slow or halt the progression of neurodegenerative diseases. Founded by Professor Lars Lannfelt, the company is renowned for its groundbreaking work in Alzheimer's disease, particularly with the development of Leqembi® (lecanemab), the world's first drug proven to slow cognitive decline in early Alzheimer's disease patients.

BioArctic operates through strategic alliances, with a significant partnership with Eisai, a global pharmaceutical company. Together, they developed lecanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody targeting aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab has been granted approval in the U.S., Japan, China, and South Korea, with pending applications in several other countries including the European Union and Canada. The drug's efficacy was demonstrated in the Phase 3 Clarity AD study, which met all primary and key secondary endpoints with statistically significant results.

Recently, BioArctic and Eisai presented new data on lecanemab at the 2024 International Conference on Alzheimer's and Parkinson's Diseases, showcasing its binding properties and lower incidence of adverse events compared to other antibodies. This data reinforces the importance of early diagnosis and treatment in managing Alzheimer's disease.

In addition to Alzheimer's research, BioArctic's portfolio includes antibodies targeting Parkinson's disease and ALS. They employ their proprietary BrainTransporter™ technology, which enhances the delivery of therapeutic antibodies across the blood-brain barrier, potentially increasing the efficacy of treatments.

BioArctic is also committed to sustainable innovation and has integrated environmental, social, and corporate governance principles into its operations, recently earning a place on the Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index. This recognition underscores the company's dedication to responsible business practices and the positive societal impact of its research and development activities.

Financially, BioArctic benefits from royalty payments related to lecanemab sales and milestone payments tied to regulatory approvals. In the first quarter of 2024, Leqembi generated JPY 2.83 billion in sales, resulting in SEK 18 million in royalties for BioArctic, with projections for significant revenue growth in the coming year.

Rhea-AI Summary

BioAge Labs reported Q3 2024 financial results and business updates. Key highlights include the initiation of Phase 2 STRIDES trial testing azelaprag with tirzepatide for obesity, and completion of a $238.3M IPO. The company reported R&D expenses of $20.0M (up from $6.5M in Q3 2023), G&A expenses of $4.7M, and a net loss of $23.4M. With approximately $334.5M in cash and cash equivalents, BioAge expects to fund operations into 2029. The company also appointed former GSK CEO Jean-Pierre Garnier as Board Chair.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.61%
Tags
-
Rhea-AI Summary

BioArctic AB has unveiled its proprietary BrainTransporter (BT) platform at the PEGS conference in Barcelona. The technology demonstrates up to 70-fold higher penetration of antibodies across the blood-brain barrier using Transferrin Receptor-mediated transport, without negative effects on hematological safety. The platform shows rapid, broad, and deep distribution of amyloid-beta antibodies across the brain in preclinical models. In April 2024, BioArctic and Eisai entered a research evaluation agreement for BAN2802, combining BT technology with an Alzheimer drug candidate.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
none
-
Rhea-AI Summary

BioArctic AB (NASDAQ STOCKHOLM: BIOA B) has announced it will release its Q3 2024 report for July-September on November 14, 2024, at 08:00 CET. The company will host an audiocast with teleconference in English at 09:30 CET where CEO Gunilla Osswald and CFO Anders Martin-Löf will present the quarterly results and conduct a Q&A session. Participants can join via webcast or teleconference, with both options requiring pre-registration. The presentation will be available on-demand afterward on BioArctic's corporate website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
conferences earnings
Rhea-AI Summary

BioAge Labs announced new preclinical data presentations for azelaprag, their oral APJ agonist, at ObesityWeek 2024. The studies demonstrated that azelaprag enhanced weight loss when combined with various appetite suppressants in obese mice on high-fat diets. As a monotherapy, azelaprag showed protection against excess weight gain, improved body composition, and increased physical activity and energy expenditure. The data supports azelaprag's potential as a novel obesity treatment, both as a standalone therapy and in combination with other medications like semaglutide, tirzepatide, danuglipron, and rimonabant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
conferences clinical trial
-
Rhea-AI Summary

BioArctic AB's partner Eisai has completed a rolling Biologics License Application (BLA) submission to the FDA for Leqembi subcutaneous autoinjector for weekly maintenance dosing in early Alzheimer's disease treatment. The autoinjector would allow for 15-second home administration after completing the initial IV phase. The application is based on Clarity AD open-label extension study data. Leqembi is currently approved in multiple countries including the US, Japan, and China, with pending applications in 10 other regions. The FDA is also reviewing a separate application for monthly IV maintenance dosing with a PDUFA date of January 25, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.16%
Tags
none
-
Rhea-AI Summary

BioArctic AB (NASDAQ Stockholm: BIOA B) partner Eisai presented three-year data for lecanemab (Leqembi®) at CTAD congress, showing increased benefits for early Alzheimer's patients. The drug demonstrated a 30% reduction in disease stage progression risk, with 46% of patients with low brain amyloid levels showing improved or maintained cognition after three years. The CDR-SB benefit expanded to -0.95 compared to ADNI-population at 36 months. Safety profile remained consistent, with most ARIA occurring in first six months. Data suggests continued treatment benefits even after plaque clearance, particularly in early-stage patients. In Great Britain's approved population, treatment showed 33% CDR-SB decline slowing versus 27% in total study population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
Rhea-AI Summary

BioArctic AB's partner Eisai reported Leqembi® global revenue of JPY 10 billion for Q3 2024, marking a 60% increase from Q2 2024's JPY 6.3 billion. This resulted in a royalty payment of approximately SEK 70 million to BioArctic. Eisai leads Leqembi's development and regulatory submissions globally, with Biogen co-commercializing the product. BioArctic maintains commercialization rights in the Nordic region and is preparing for joint commercialization with Eisai pending European approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
-
Rhea-AI Summary

BioArctic AB announced that its co-founder, Professor Lars Lannfelt, received the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD congress in Madrid. The award recognizes his pioneering work in Alzheimer's disease research and drug development, particularly his contributions leading to lecanemab, a disease-modifying treatment for early Alzheimer's approved in multiple countries including the U.S., Japan, and China. Lannfelt founded BioArctic in 2003 with Pär Gellerfors to develop antibody treatments based on his discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab, developed in collaboration with Eisai, works by binding to and clearing specific forms of amyloid-beta from the brain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
Rhea-AI Summary

BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in the Jefferies London Healthcare Conference. CEO and co-founder Kristen Fortney, PhD, will deliver a presentation at the conference, scheduled for November 19-21, 2024. The presentation will be available on-demand, with a live webcast scheduled for November 19 at 1:00-1:25 PM GMT. Interested parties can access the presentation replay through BioAge's investor relations website for approximately 30 days post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
conferences
Rhea-AI Summary

BioArctic AB announced that its founder, Lars Lannfelt, will receive the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD Conference in Madrid from October 29 to November 1. The conference will feature presentations on lecanemab, including data on its clinical practice use and plasma biomarkers in the AHEAD 3-45 trial. Key sessions include three symposia focusing on lecanemab's continued treatment importance, real-world evidence from the U.S. and Japan, and combination therapy considerations. Two oral presentations will discuss lecanemab's treatment efficacy and AI-derived prognostic covariates, along with a poster presentation on transitioning from clinical trials to practice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none

FAQ

What is the current stock price of BioAge Labs (BIOA)?

The current stock price of BioAge Labs (BIOA) is $5.94 as of December 23, 2024.

What is the market cap of BioAge Labs (BIOA)?

The market cap of BioAge Labs (BIOA) is approximately 220.1M.

What is BioArctic AB known for?

BioArctic AB is known for developing innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease. They created Leqembi®, the first drug proven to slow cognitive decline in early Alzheimer's patients.

Who are BioArctic's main partners?

BioArctic's main partner is Eisai, a global pharmaceutical company. Together, they developed the Alzheimer's drug lecanemab.

What is Leqembi® (lecanemab)?

Leqembi® (lecanemab) is a monoclonal antibody targeting amyloid-beta (Aβ) protofibrils to treat Alzheimer's disease. It is approved in the U.S., Japan, China, and South Korea.

How does BioArctic's BrainTransporter™ technology work?

BioArctic's BrainTransporter™ technology enhances the delivery of therapeutic antibodies across the blood-brain barrier, potentially increasing the efficacy of treatments for neurodegenerative diseases.

What recent achievements has BioArctic made?

BioArctic has recently presented new data on lecanemab at the 2024 International Conference on Alzheimer's and Parkinson's Diseases, showcasing its efficacy and lower incidence of adverse events.

What is BioArctic's commitment to sustainability?

BioArctic is committed to sustainable innovation, integrating environmental, social, and corporate governance principles, earning a place on the Nasdaq OMX Sweden Small Cap 30 ESG Responsibility Index.

What are BioArctic's financial highlights?

In the first quarter of 2024, Leqembi sales generated JPY 2.83 billion, resulting in SEK 18 million in royalties for BioArctic. The company projects significant revenue growth in the coming year.

What are BioArctic's future projects?

BioArctic is involved in research projects targeting Parkinson's disease, ALS, and other Alzheimer's treatments, utilizing their proprietary BrainTransporter™ technology.

How does lecanemab work?

Lecanemab targets aggregated soluble and insoluble forms of amyloid-beta (Aβ), helping to clear Aβ protofibrils and plaques from the brain, thereby slowing cognitive decline in early Alzheimer's patients.

What regulatory approvals does lecanemab have?

Lecanemab is approved in the U.S., Japan, China, and South Korea, with pending applications in the EU, Australia, Brazil, Canada, and several other countries.

BioAge Labs, Inc.

Nasdaq:BIOA

BIOA Rankings

BIOA Stock Data

220.11M
7.50M
3.62%
70.68%
6.16%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
RICHMOND